论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
阿布替尼成功治疗口周皮炎一例
Authors Teng Y , Ren M , Ding Y , Yang X, Fan Y, Tao X
Received 31 August 2023
Accepted for publication 12 October 2023
Published 24 October 2023 Volume 2023:16 Pages 3035—3038
DOI https://doi.org/10.2147/CCID.S433561
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jeffrey Weinberg
Abstract: Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was successfully treated using the Janus kinase (JAK) inhibitor, abrocitinib. This treatment exhibited both good efficacy and safety. Abrocitinib, as a JAK inhibitor, holds promise as a potential therapy for cases of POD that might be resistant to conventional therapies.
Keywords: JAK inhibitors, abrocitinib, perioral dermatitis